Stocks plunge as Trump initiates trade war

Global stocks sunk, a day after US President Donald Trump announced sweeping new tariffs that are forecast to raise prices and weigh on growth in the United States and around the world, reports the Saudi Gazette.

Stock markets in the Asia-Pacific region fell for a second day, hot on the heels of the S&P 500, which had its worst day since Covid crashed the economy in 2020. Nike, Apple and Target were among big consumer names worst hit, all of them sinking by more than 9%.

At the White House, Trump told reporters the US economy would "boom" thanks to the minimum 10% tariff he plans to slap on global imports in the hope of boosting federal revenues and bringing American manufacturing home.

The Republican president plans to hit products from dozens of other countries with far higher levies, including trade partners such as China and the European Union.

China, which is facing an aggregate 54% tariff, and the EU, which faces duties of 20%, both vowed retaliation on Thursday. French President Emmanuel Macron called for European firms to suspend planned investment in the United States.

Tariffs are taxes on goods imported from other countries, and Trump's plan that he announced on Wednesday would hike such duties to some of the highest levels in more than 100 years.

In morning trading on Friday, Japan's benchmark Nikkei 225 index fell by 2.7% and Australia's ASX 200 was down by 1.6%. The Kospi in South Korea was flat to slightly lower. Markets in mainland China and Hong Kong were closed for the Qingming Festival.

Earlier on Thursday, the S&P 500 — which tracks 500 of the biggest American firms — plunged 4.8%, shedding roughly US$2 trillion in value. The Dow Jones closed about 4% lower, while the Nasdaq tumbled roughly 6%. The US shares sell-off has been going on since mid-February amid trade war fears.

Britain’s FTSE 100 share index dropped 1.5% and other European markets also fell, echoing declines from Japan to Hong Kong.

On Thursday at the White House, Trump doubled down on a high-stakes gambit aimed at reversing decades of US-led liberalization that shaped the global trade order.

"I think it's going very well," he said. "It was an operation like when a patient gets operated on, and it's a big thing. I said this would exactly be the way it is."

He added, "The markets are going to boom. The stock is going to boom. The country is going to boom."

Contradicting White House aides who insisted the new tariffs were not a negotiating tactic, Trump signalled he might be open to a deal with trade partners "if somebody said we're going to give you something that's so phenomenal".

On Thursday, Canada's Prime Minister Mark Carney said that country would retaliate with a 25% levy on vehicles imported from the US.

Trump last month imposed tariffs of 25% on Canada and Mexico, though he did not announce any new duties on Wednesday against the North American trade partners.

Firms now face a choice of swallowing the tariff cost, working with partners to share that burden, or passing it on to consumers — and risking a drop in sales.

That could have a major impact as US consumer spending amounts to about 10% to 15% of the world economy, according to some estimates.

While stocks fell on Thursday, the price of gold, which is seen as a safer asset in times of turbulence, touched a record high of US$3,167.57 an ounce at one point on Thursday, before falling back.

The dollar also weakened against many other currencies.

In Europe, the tariffs could drag down growth by nearly a percentage point, with a further hit if the bloc retaliates, according to analysts at Principal Asset Management.

In the US, a recession is likely to materialize without other changes, such as big tax cuts, which Trump has also promised, warned Seema Shah, chief global strategist at the firm. She said Trump's goals of boosting manufacturing would be a years-long process "if it happens at all".

"In the meantime, the steep tariffs on imports are likely to be an immediate drag on the economy, with limited short-term benefit," she said.

On Thursday, Stellantis, which makes Jeep, Fiat and other brands, said it was temporarily halting production at a factory in Toluca, Mexico and Windsor, Canada. It said the move, a response to Trump's 25% tax on car imports, would also lead to temporary layoffs of 900 people at five plants in the US that supply those factories.

Nike, which makes much of its sportswear in Asia, was among the hardest hit on the S&P, with shares down 14%. Shares in Apple, which relies heavily on China and Taiwan, tumbled 9%. Other retailers also fell, with Target down roughly 10%.

Motorbike maker Harley-Davidson – which was subject of retaliatory tariffs by the EU during Trump's first term as president – fell 10%.

In Europe, shares in sportswear firm Adidas fell more than 10%, while stocks in rival Puma tumbled more than 9%.

"You're seeing retailers get destroyed right now because tariffs extended to countries we did not expect," said Jay Woods, chief global strategy at Freedom Capital Markets, adding that he expected more turbulence ahead.

Can Trump impose tariffs on Chinese drugs?

According to The Hill, President Trump’s tariffs on China are in place and hitting all products imported from the country — including a number of pharmaceuticals that Americans rely upon.

Chinese imports account for a significant proportion of US prescriptions and over the counter drugs. Many of the Chinese-produced medicines are generics, which account for 91 percent of prescriptions dispensed in the United States.

“The Chinese market is a key supplier for key starting materials and Active Pharmaceutical Ingredient (API) to the generic supply chain,” said John Murphy, president and CEO of the Association for Accessible Medicines (AAM). 

“I will say they’re sort of less important any longer for the actual finished fill and final manufacturing,” Murphy noted. “But really, it’s the rare minerals, the key starting materials which are obviously critical to the supply chain.” 

Stakeholders were hopeful that medications would be spared from tariffs. Some noted that the US is a signatory to the World Trade Organization’s (WTO) 1994 Agreement on Trade in Pharmaceutical Products which calls for the elimination of tariffs on many pharmaceutical products. China has vowed to sue over the 10 percent tariffs, which it says are in violation of WTO rules. 

But a White House official said no exceptions are planned, and the administration will not be recognizing the WTO agreement. 

The country’s dependence on China to maintain pharmaceutical supply chains has long been an issue that lawmakers on both sides of the aisle have sought to address.

In 2018, the US-China Economic and Security Review Commission noted that the country was “heavily dependent” on drugs and API originating from China.

A 2023 analysis from the Atlantic Council found that the value of Chinese-imported APIs has continued to grow in recent years. 

According to Monica de Bolle, a senior fellow at the Peterson Institute for International Economics, the US isn’t unique in its dependence on China for drugs, noting that the European Union is similarly reliant.   

De Bolle said China’s dominance in the market grew as it sought to enhance its drug producing capacity while US pharmaceutical companies turned to other manufacturing pursuits. 

“What happened is that we developed this huge biotech sector where we have a lot of stuff going on,” said de Bolle. “The manufacturing market just turned to producing these more sophisticated drugs; the stuff that’s used in treatments, the stuff that’s going through clinical trials.” 

“That’s why we went from, you know, producing a lot of these things to not producing many of these things and buying them from elsewhere. And elsewhere eventually became China,” she added. 

The margins for manufacturing generic drugs are razor-thin, and any disruptions to the supply chain are apt to cause shortages or delays. 

“That additional 10 percent tariff is going to have a fairly significant impact on the cost of goods for the generic and by a similar supply chain,” said Murphy. “We don’t hold massive stockpiles of generic drugs in the United States. It’s a fairly just-in-time inventory.” 

According to Murphy, some manufacturers may find it economically unviable to produce generic drugs, resulting in shortages. 

Across all industries, analysts have warned that increased costs brought on by tariffs will be passed to consumers. But some manufacturers may instead drop out of the market entirely rather than pass on costs, partly due to a key provision in the Inflation Reduction Act (IRA).

As part of its cost-cutting measures, the IRA included a provision that requires drug makers to pay Medicaid a rebate if the price of their drugs rises faster than the rate of inflation.  

Tom Kraus, vice president of government relations at the American Society of Health-System Pharmacists, said incurring that penalty on top of tariffs could mean more than just shortages. 

“You’ve got to sort of factor in paying that penalty, which is going to make you less profitable or you’re going to have to drop out of the market,” said Kraus. 

He noted that group purchasing organizations, companies that help hospitals and pharmacies buy drugs and save money, may decide that manufacturers whose products originate from China are too expensive and turn away from them entirely.